Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Program for the potential use of PLX cells in the treatment of Single Patient suffering from complications associated with COVID-19

Next Previous
Search
Trial Profile

Expanded Access Program for the potential use of PLX cells in the treatment of Single Patient suffering from complications associated with COVID-19

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 03 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-19 infection therapeutics Charite University of Medicine Berlin/Pluristem Therapeutics (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections; Respiratory insufficiency
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Pluri

    • Most Recent Events

    • 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
    • 14 May 2020 According to a Pluristem Therapeutics media release, 1 patient has completed a 28-day follow up period.
    • 14 May 2020 Results presented in the Pluristem media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top